Antiviral therapy in cytomegalovirus-positive ulcerative colitis: A systematic review and meta-analysis

Table 1 Characteristics of the included studies and patients on cytomegalovirus in ulcerative colitis

Ref.	Year of publication	Type	Design	n		Included patients	Severity criteria	Method of diagnosis	Anti-viral tx	Follow-up (mo)	Short-term colectomy rate		Long-term colectomy rate
				TX	C						TX	C	TX	C
Omiya et al[8]	2010	Full	P1	10	10	Moderate to severe UC	Seo’s score	Tissue PCR (IHC/HE -)	GCV	12	0/10	0/10	3/10	0/10
Zeki et al[9]1	2010	Abstract	R2	7	10	UC (no severity data)	NA	HE/IHC+	GCV-5,	12	4/7	7/10	4/7	7/10
									VGCV-2
Maconi et al[10]3	2011	Abstract	R2	6	14	Moderate to severe UC	Mayo/Baron score	HE/IHC+	GCV	12	0/6	0/14	0/6	2/13
Criscuoli et al[17]	2011	Full	P1	7	21	Moderate to severe UC	Truelove/Witts	IHC +, pp65+	GCV-5 FC-2	12	2/7	4/21	2/7	4/18
Kim et al[12]	2012	Full	P1	14	17	Moderate to severe UC	Mayo/Baron score	HE/IHC/PCR+	GCV	hospitalization	3/14	0/17	NA	NA
Roblin et al[13]3	2011	Full	P1	8	8	Moderate to severe UC, failure of CS +rescue therapy (IFX/CSA)	Mayo	qPCR, IHC/HE-	GCV	≥ 10	1/8	2/8	3/8	2/8
Al-Zafiri et al[14]3	2012	Full	R2	7	8	Hospitalized UC	NA	IHC/HE+	GCV	hospitalization	3/7	0/8	NA	NA
Maruyama et al[15]	2012	Abstract	R2	4	12	Moderate to severe UC	NA	IHC/HE+	GCV	Hospitalization	3/4	0/12	NA	NA
Kopylov et al[16]	2013	Full	R2	7	6	UC	NA	IHC/HE+	GCV-6 VGCV-1	13	1/7	0/6	3/7	0/6

¹P: prospective design;

²R: retrospective design;

³Some of the data was obtained through personal communication; TX: Patients treated with antivirals; C: Patients who did not receive antivirals. PCR: Polymerase chain reaction; qPCR: Quantitative PCR; IHC: Immunohistochemistry; HE: Hematoxylin-eosin staining; pp65: Antigenemia; GCV: Gancyclovir; VGCV: Valgancyclovir; FC: Foscarnet. Short -term outcome- during the initial hospitalization or within 30 d of the diagnosis; long-term outcome- > 3 mo after the initial hospitalization.